688373 盟科药业
已收盘 12-31 15:00:01
资讯
新帖
简况
盟科药业董事兼首席财务官李峙乐因个人原因辞职
中金财经 · 12:21
盟科药业董事兼首席财务官李峙乐因个人原因辞职
盟科药业（688373）披露董事、高级管理人员离任公告，12月31日股价上涨1.0%
证券之星 · 12-31 22:31
盟科药业（688373）披露董事、高级管理人员离任公告，12月31日股价上涨1.0%
每周股票复盘：盟科药业（688373）12.13%限售股将解禁
证券之星 · 2025-12-28
每周股票复盘：盟科药业（688373）12.13%限售股将解禁
盟科药业（688373）披露首次公开发行部分限售股上市流通公告，12月23日股价下跌1.95%
证券之星 · 2025-12-23
盟科药业（688373）披露首次公开发行部分限售股上市流通公告，12月23日股价下跌1.95%
12月4日盟科药业发布公告，股东减持73.56万股
证券之星 · 2025-12-04
12月4日盟科药业发布公告，股东减持73.56万股
每周股票复盘：盟科药业（688373）终止向特定对象发行股票
证券之星 · 2025-11-23
每周股票复盘：盟科药业（688373）终止向特定对象发行股票
大股东持续反对，盟科药业定增易主事项折戟
北京商报 · 2025-11-19
大股东持续反对，盟科药业定增易主事项折戟
盟科药业（688373）披露终止向特定对象发行股票事项，11月17日股价下跌3.52%
证券之星 · 2025-11-17
盟科药业（688373）披露终止向特定对象发行股票事项，11月17日股价下跌3.52%
每周股票复盘：盟科药业（688373）亏损大幅缩窄39.04%
证券之星 · 2025-11-16
每周股票复盘：盟科药业（688373）亏损大幅缩窄39.04%
每周股票复盘：盟科药业（688373）康替唑胺片新增供应商获批
证券之星 · 2025-11-09
每周股票复盘：盟科药业（688373）康替唑胺片新增供应商获批
盟科药业（688373）披露取消监事会并修订公司章程议案获通过，11月07日股价上涨0.14%
证券之星 · 2025-11-07
盟科药业（688373）披露取消监事会并修订公司章程议案获通过，11月07日股价上涨0.14%
盟科药业（688373）披露关于获得药品补充申请及药物临床试验补充申请批准通知书，11月05日股价下跌0.28%
证券之星 · 2025-11-05
盟科药业（688373）披露关于获得药品补充申请及药物临床试验补充申请批准通知书，11月05日股价下跌0.28%
盟科药业2025年前三季度实现营收1.04亿元 同比增长6.58%
证券日报 · 2025-11-05
盟科药业2025年前三季度实现营收1.04亿元 同比增长6.58%
每周股票复盘：盟科药业（688373）股东户数增14.18%
证券之星 · 2025-11-02
每周股票复盘：盟科药业（688373）股东户数增14.18%
盟科药业（688373）披露拟取消监事会并变更募投资金用途，10月30日股价下跌0.94%
证券之星 · 2025-10-30
盟科药业（688373）披露拟取消监事会并变更募投资金用途，10月30日股价下跌0.94%
图解盟科药业三季报：第三季度单季净利润同比增长39.04%
证券之星 · 2025-10-28
图解盟科药业三季报：第三季度单季净利润同比增长39.04%
每周股票复盘：盟科药业（688373）将召开临时股东大会
证券之星 · 2025-10-26
每周股票复盘：盟科药业（688373）将召开临时股东大会
盟科药业（688373）披露拟取消监事会并修订公司章程，10月22日股价下跌2.03%
证券之星 · 2025-10-22
盟科药业（688373）披露拟取消监事会并修订公司章程，10月22日股价下跌2.03%
每周股票复盘：盟科药业（688373）MRX-5临床推进及募投项目变更
证券之星 · 2025-10-19
每周股票复盘：盟科药业（688373）MRX-5临床推进及募投项目变更
盟科药业定增风波背后：治理分歧、持续亏损与股东减持三重困局
新浪证券 · 2025-10-17
盟科药业定增风波背后：治理分歧、持续亏损与股东减持三重困局
加载更多
公司概况
公司名称：
上海盟科药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-05
主营业务：
上海盟科药业股份有限公司的主营业务是新药研发，并采用MAH模式委托有资质的原料药和制剂生产企业进行生产。公司的主要产品是MRX-1康替唑胺片、MRX-4、MRX-8、MRX-5。
发行价格：
8.16
{"stockData":{"symbol":"688373","market":"SH","secType":"STK","nameCN":"盟科药业","latestPrice":6.04,"timestamp":1767164401000,"preClose":5.98,"halted":0,"volume":4285426,"delay":0,"changeRate":0.01,"floatShares":525000000,"shares":656000000,"eps":-0.5232,"marketStatus":"已收盘","change":0.06,"latestTime":"12-31 15:00:01","open":6.03,"high":6.04,"low":5.95,"amount":25698000,"amplitude":0.0151,"askPrice":6.04,"askSize":836,"bidPrice":6.03,"bidSize":120,"shortable":0,"etf":0,"ttmEps":-0.5232,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.98,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":6.58,"lowLimit":5.38,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":655605491,"isCdr":false,"pbRate":15.37,"roa":"--","roe":"--","epsLYR":-0.67,"committee":-0.267475,"marketValue":3960000000,"turnoverRate":0.0082,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","afterMarket":{"amount":0,"volume":0,"close":6.04,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":5.98},"floatMarketCap":3174000000},"requestUrl":"/m/hq/s/688373","defaultTab":"news","newsList":[{"id":"2600856080","title":"盟科药业董事兼首席财务官李峙乐因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2600856080","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600856080?lang=zh_cn&edition=full","pubTime":"2026-01-01 12:21","pubTimestamp":1767241265,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月1日发布公告，公司董事、副总经理、首席财务官李峙乐先生因个人原因，已于近日递交书面辞职报告，辞去其在上市公司担任的全部职务，包括董事、董事会提名委员会委员、副总经理及首席财务官。公司表示将尽快完成董事补选及财务负责人聘任工作。截至公告日，李峙乐先生直接持有公司2,636,714股股份，并通过境外架构间接持有公司股份，离任后其将继续遵守相关股份减持的承诺与规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260101/31910001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2595777246","title":"盟科药业（688373）披露董事、高级管理人员离任公告，12月31日股价上涨1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777246","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777246?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:31","pubTimestamp":1767191475,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，盟科药业报收于6.04元，较前一交易日上涨1.0%，最新总市值为39.6亿元。该股当日开盘6.03元，最高6.04元，最低5.95元，成交额达2569.8万元，换手率为0.82%。因个人原因，李峙乐先生辞去公司董事、董事会提名委员会委员、副总经理、首席财务官职务，辞职自送达董事会之日起生效。公告显示，公司董事会正常运作及经营管理不会因李峙乐先生的辞职而受到影响，后续将尽快完成相关补选及聘任工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2594624799","title":"每周股票复盘：盟科药业（688373）12.13%限售股将解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2594624799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594624799?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:10","pubTimestamp":1766869821,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，盟科药业报收于6.08元，较上周的6.16元下跌1.3%。本周，盟科药业12月22日盘中最高价报6.2元。本周关注点公司公告汇总：盟科药业12.13%首发前限售股将于2026年1月5日解禁上市。公司公告汇总上海盟科药业股份有限公司首次公开发行部分限售股将于2026年1月5日上市流通，本次上市流通数量为79,523,500股，占公司总股本的12.13%。上述股东均已履行股份锁定及相关承诺，保荐机构中国国际金融股份有限公司对本次解禁无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2593998194","title":"盟科药业（688373）披露首次公开发行部分限售股上市流通公告，12月23日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593998194","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593998194?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:58","pubTimestamp":1766483928,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，盟科药业报收于6.04元，较前一交易日下跌1.95%，最新总市值为39.6亿元。该股当日开盘6.16元，最高6.16元，最低6.03元，成交额达4100.09万元，换手率为1.29%。公司近日发布公告称，上海盟科药业股份有限公司首次公开发行部分限售股将于2026年1月5日上市流通。本次上市流通数量为79,523,500股，占公司总股本的12.13%。涉及股东包括Genie Pharma、盟科香港及新沂优迈，上述股东均为首发前限售股股东。保荐机构中国国际金融股份有限公司对本次解禁无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300029390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2588891998","title":"12月4日盟科药业发布公告，股东减持73.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588891998","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588891998?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:01","pubTimestamp":1764849683,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日盟科药业发布公告《盟科药业:上海盟科药业股份有限公司股东减持计划时间届满暨减持股份结果公告》，其股东MicuRx(HK) Limited于2025年9月5日至2025年12月4日间合计减持73.56万股，占公司目前总股本的0.1122%，变动期间该股股价下跌23.38%，截止12月4日收盘报6.13元。股东增减持详情见下表：根据盟科药业2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400034874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2585108038","title":"每周股票复盘：盟科药业（688373）终止向特定对象发行股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108038","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108038?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:59","pubTimestamp":1763834347,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，盟科药业报收于6.33元，较上周的7.39元下跌14.34%。本周，盟科药业11月17日盘中最高价报7.42元。本周关注点公司公告汇总：盟科药业终止向南京海鲸药业发行163,901,373股股份的计划。上海盟科药业股份有限公司于2025年11月15日召开董事会，审议通过终止向特定对象发行股票事项。此前公司拟向南京海鲸药业发行163,901,373股股份募集资金103,257.86万元，并获股东大会批准。本次终止不会对公司生产经营造成实质性影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2584581945","title":"大股东持续反对，盟科药业定增易主事项折戟","url":"https://stock-news.laohu8.com/highlight/detail?id=2584581945","media":"北京商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584581945?lang=zh_cn&edition=full","pubTime":"2025-11-19 18:53","pubTimestamp":1763549580,"startTime":"0","endTime":"0","summary":" 盟科药业最新公告显示，公司拟终止向特定对象发行股票事项。而此次交易前，盟科药业无控股股东、无实控人。 盟科药业表示，截至目前，公司主要股东Genie Pharma持续反对公司按照股东大会决议推进发行方案的执行，与公司其他股东、公司管理层之间存在较大分歧。 随着定增事项获股东大会通过，市场普遍认为盟科药业此次定增事项得以顺利进行，不过如今仍已失败收场。盟科药业表示，目前公司生产经营正常。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-19/doc-infxxwtu4519385.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-19/doc-infxxwtu4519385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2584621973","title":"盟科药业（688373）披露终止向特定对象发行股票事项，11月17日股价下跌3.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584621973","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584621973?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:18","pubTimestamp":1763389095,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，盟科药业报收于7.13元，较前一交易日下跌3.52%，最新总市值为46.74亿元。公司近日发布公告称，上海盟科药业股份有限公司于2025年11月15日召开董事会，审议通过终止向特定对象发行股票事项。此前公司拟向南京海鲸药业发行163,901,373股股份募集资金103,257.86万元，并获股东大会批准。为维护全体股东利益，董事会决定终止该事项，后续将协商签署终止协议并履行信息披露义务。本次终止不会对公司生产经营造成实质性影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700036911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2583651433","title":"每周股票复盘：盟科药业（688373）亏损大幅缩窄39.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651433","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651433?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:48","pubTimestamp":1763236094,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，盟科药业报收于7.39元，较上周的7.19元上涨2.78%。本周，盟科药业11月14日盘中最高价报7.61元。本周关注点来自机构调研要点：公司2025年第三季度归母净利润亏损同比大幅减少39.04%。公司2025年第三季度实现营业收入3701.55万元，同比增长0.52%，归母净利润为-5486.17万元，亏损同比大幅减少39.04%，环比大幅减少60.44%，亏损大幅缩窄得益于销售进一步放量、成本费用控制以及运营效率提升，感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2582686903","title":"每周股票复盘：盟科药业（688373）康替唑胺片新增供应商获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2582686903","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582686903?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:17","pubTimestamp":1762629431,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，盟科药业报收于7.19元，较上周的7.52元下跌4.39%。本周，盟科药业11月3日盘中最高价报7.69元。本周关注点公司公告汇总：康替唑胺片获批新增受托生产企业及原料药供应商。康替唑胺片获批新增江苏宣泰药业有限公司为受托生产企业，并批准重庆博腾制药科技股份有限公司为其原料药供应商，有利于保障产品稳定供应。康替唑胺片为新一代恶唑烷酮类抗菌药，用于治疗复杂性皮肤和软组织感染，2021年6月在中国获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2581088915","title":"盟科药业（688373）披露取消监事会并修订公司章程议案获通过，11月07日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581088915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581088915?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:26","pubTimestamp":1762525590,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，盟科药业报收于7.19元，较前一交易日上涨0.14%，最新总市值为47.14亿元。该股当日开盘7.21元，最高7.23元，最低7.12元，成交额达5884.13万元，换手率为1.56%。所有议案均获通过，无被否决议案。会议表决程序合法有效，出席股东所持表决权占公司总表决权的38.7269%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2581781775","title":"盟科药业（688373）披露关于获得药品补充申请及药物临床试验补充申请批准通知书，11月05日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581781775","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581781775?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:20","pubTimestamp":1762352435,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，盟科药业报收于7.19元，较前一交易日下跌0.28%，最新总市值为47.14亿元。近日，上海盟科药业股份有限公司发布自愿披露公告，称公司收到国家药品监督管理局出具的《药品补充申请批准通知书》和《药物临床试验补充申请批准通知书》。根据公告，康替唑胺片获批新增江苏宣泰药业有限公司为受托生产企业，并批准重庆博腾制药科技股份有限公司为其原料药供应商，有利于保障产品稳定供应。相关临床试验已获国家药监局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2581714552","title":"盟科药业2025年前三季度实现营收1.04亿元 同比增长6.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581714552","media":"证券日报 ","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581714552?lang=zh_cn&edition=full","pubTime":"2025-11-05 13:03","pubTimestamp":1762318980,"startTime":"0","endTime":"0","summary":"本报讯 上海盟科药业股份有限公司近日披露了2025年第三季度报告，公司前三季度展现出良好的经营改善势头，核心财务指标持续向好，亏损幅度同比大幅收窄，营业收入持续增长，商业化进一步放量。 盟科药业在2025年1月至9月实现营业收入1.04亿元，同比增长6.58%。公司前三季度毛利率为84.88%，较去年同期提高2.65个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwincu9611734.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwincu9611734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688373"],"gpt_icon":0},{"id":"2580047223","title":"每周股票复盘：盟科药业（688373）股东户数增14.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580047223","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580047223?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:55","pubTimestamp":1762037713,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，盟科药业报收于7.52元，较上周的7.57元下跌0.66%。本周，盟科药业10月28日盘中最高价报7.8元。股本股东变化股东户数变动截至2025年9月30日，公司股东户数为1.65万户，较6月30日增加2048.0户，增幅14.18%。业绩披露要点财务报告盟科药业2025年三季报显示，公司主营收入1.04亿元，同比上升6.58%；归母净利润-1.94亿元，同比上升33.56%；扣非净利润-2.01亿元，同比上升33.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2579312379","title":"盟科药业（688373）披露拟取消监事会并变更募投资金用途，10月30日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579312379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579312379?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:17","pubTimestamp":1761833862,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，盟科药业报收于7.36元，较前一交易日下跌0.94%，最新总市值为48.25亿元。近日，盟科药业发布《2025年第三次临时股东大会会议资料》，公告公司拟对治理结构进行调整。此外，公告还披露了续聘立信会计师事务所为2025年度审计机构、变更部分募集资金用途以及为董事及高管购买责任险等事项。本次股东大会将采取现场与网络投票相结合方式，现场会议定于2025年11月7日举行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000045049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2578627625","title":"图解盟科药业三季报：第三季度单季净利润同比增长39.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578627625","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578627625?lang=zh_cn&edition=full","pubTime":"2025-10-28 03:02","pubTimestamp":1761591740,"startTime":"0","endTime":"0","summary":"证券之星消息，盟科药业2025年三季报显示，公司主营收入1.04亿元，同比上升6.58%；归母净利润-1.94亿元，同比上升33.56%；扣非净利润-2.01亿元，同比上升33.93%；其中2025年第三季度，公司单季度主营收入3701.55万元，同比上升0.52%；单季度归母净利润-5486.17万元，同比上升39.04%；单季度扣非净利润-5722.81万元，同比上升37.84%；负债率64.57%，财务费用630.62万元，毛利率84.88%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800002368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373"],"gpt_icon":0},{"id":"2578502859","title":"每周股票复盘：盟科药业（688373）将召开临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2578502859","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578502859?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:47","pubTimestamp":1761418029,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，盟科药业报收于7.57元，较上周的7.97元下跌5.02%。本周，盟科药业10月20日盘中最高价报8.14元。本周关注点公司公告汇总：盟科药业将于2025年11月7日召开第三次临时股东大会，审议取消监事会等多项议案。公司公告汇总上海盟科药业股份有限公司将于2025年11月7日14:00在上海市浦东新区爱迪生路53号召开2025年第三次临时股东大会，采用现场投票与网络投票相结合方式，网络投票通过上海证券交易所系统进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2577135444","title":"盟科药业（688373）披露拟取消监事会并修订公司章程，10月22日股价下跌2.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577135444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577135444?lang=zh_cn&edition=full","pubTime":"2025-10-22 17:17","pubTimestamp":1761124640,"startTime":"0","endTime":"0","summary":"截至2025年10月22日收盘，盟科药业报收于7.72元，较前一交易日下跌2.03%，最新总市值为50.61亿元。该股当日开盘7.85元，最高8.03元，最低7.7元，成交额达1.23亿元，换手率为3.0%。其中最受投资者关注的为“关于取消监事会并修订《公司章程》的议案”，该议案属于特别决议事项，需经出席会议股东所持表决权的三分之二以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200027243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2576046545","title":"每周股票复盘：盟科药业（688373）MRX-5临床推进及募投项目变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2576046545","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576046545?lang=zh_cn&edition=full","pubTime":"2025-10-19 02:45","pubTimestamp":1760813111,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，盟科药业报收于7.97元，较上周的8.56元下跌6.89%。本周关注点来自机构调研要点：MRX-5中国I期临床已入组19例健康受试者，试验正常推进。来自公司公告汇总：拟将部分募投资金用于MRX-5临床试验项目，投入3,975.00万元。304临床试验为MRX-4/康替唑胺针对耐药革兰氏阳性菌感染的III期临床试验，MRX-5为针对耐药革兰氏阴性菌和非结核分枝杆菌的I期临床试验。保荐机构中金公司对本次变更无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2576085946","title":"盟科药业定增风波背后：治理分歧、持续亏损与股东减持三重困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2576085946","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576085946?lang=zh_cn&edition=full","pubTime":"2025-10-17 14:38","pubTimestamp":1760683080,"startTime":"0","endTime":"0","summary":"近日，盟科药业-U发布一则定向增发预案，拟向南京海鲸药业募集不超过10.33亿元资金。然而，这一“救命钱”并未获得公司内部一致支持，反而引发大股东与董事会之间的激烈对立，暴露出公司在治理结构、经营战略与资金链方面的多重风险。 盟科药业的定增之争，表面是融资路径的分歧，实质是公司治理、战略方向与股东信任的全面危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-10-17/doc-infuetks7209218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688373"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767268299327,"stockEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":-0.0548},{"period":"3month","weight":-0.337},{"period":"6month","weight":-0.1259},{"period":"1year","weight":0.2227},{"period":"ytd","weight":0.2227}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海盟科药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16492人(较上一季度增加14.18%)","perCapita":"36685股","listingDate":"2022-08-05","address":"上海市浦东新区中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢","registeredCapital":"65560万元","survey":" 上海盟科药业股份有限公司的主营业务是新药研发，并采用MAH模式委托有资质的原料药和制剂生产企业进行生产。公司的主要产品是MRX-1康替唑胺片、MRX-4、MRX-8、MRX-5。","listedPrice":8.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盟科药业,688373,盟科药业股票,盟科药业股票老虎,盟科药业股票老虎国际,盟科药业行情,盟科药业股票行情,盟科药业股价,盟科药业股市,盟科药业股票价格,盟科药业股票交易,盟科药业股票购买,盟科药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}